Biotechnology company mAbxience announced on Thursday that German healthcare company Fresenius SE & Co KGaA has acquired the remaining 45% of mAbxience from Insud Pharma, building on the successful partnership established between the two companies in 2022, and marking the beginning of a new phase of growth for the company.

Fresenius acquired a 55% majority stake in mAbxience in August 2022, and has consolidated the business since then. With full ownership, mAbxience's biosimilars platform is now wholly owned within Fresenius Kabi's Biopharma business, which covers the full value chain from development and manufacturing through to commercialisation.

The existing collaboration has contributed to the expansion of manufacturing capabilities, the advancement of technology transfer programmes and the strengthening of mAbxience's position as a global biopharmaceutical company. Bringing the organisations together under full ownership is expected to create a stronger platform to enhance quality and supply resilience, while supporting future innovation and broader patient access to biosimilars at a time when many biologics are losing exclusivity.

mAbxience says that it will continue to support its existing customers and partners, and that it remains fully committed to maintaining quality, reliable supply and the delivery of its ongoing commitments worldwide.

Jurgen Van Broeck, mAbxience chief executive officer, will continue to lead the business, reporting to Dr. Sang-Jin Pak, president of Biopharma at Fresenius.